These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 20570696)
1. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Lee SM; Lee YS; Choi JH; Park SG; Choi IW; Joo YD; Lee WS; Lee JN; Choi I; Seo SK Immunol Lett; 2010 Aug; 132(1-2):53-60. PubMed ID: 20570696 [TBL] [Abstract][Full Text] [Related]
2. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Weber WP; Feder-Mengus C; Chiarugi A; Rosenthal R; Reschner A; Schumacher R; Zajac P; Misteli H; Frey DM; Oertli D; Heberer M; Spagnoli GC Eur J Immunol; 2006 Feb; 36(2):296-304. PubMed ID: 16385630 [TBL] [Abstract][Full Text] [Related]
3. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Lee WS; Lee SM; Kim MK; Park SG; Choi IW; Choi I; Joo YD; Park SJ; Kang SW; Seo SK Int Immunopharmacol; 2013 Nov; 17(3):721-6. PubMed ID: 24029595 [TBL] [Abstract][Full Text] [Related]
4. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Bauer TM; Jiga LP; Chuang JJ; Randazzo M; Opelz G; Terness P Transpl Int; 2005 Jan; 18(1):95-100. PubMed ID: 15612990 [TBL] [Abstract][Full Text] [Related]
5. Suppression of T-cell response and prolongation of allograft survival in a rat model by tryptophan catabolites. Dai X; Zhu BT Eur J Pharmacol; 2009 Mar; 606(1-3):225-32. PubMed ID: 19374879 [TBL] [Abstract][Full Text] [Related]
6. T cell apoptosis by tryptophan catabolism. Fallarino F; Grohmann U; Vacca C; Bianchi R; Orabona C; Spreca A; Fioretti MC; Puccetti P Cell Death Differ; 2002 Oct; 9(10):1069-77. PubMed ID: 12232795 [TBL] [Abstract][Full Text] [Related]
7. IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T cells. Xie FT; Cao JS; Zhao J; Yu Y; Qi F; Dai XC Transpl Immunol; 2015 Oct; 33(2):69-77. PubMed ID: 26002283 [TBL] [Abstract][Full Text] [Related]
8. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844 [TBL] [Abstract][Full Text] [Related]
9. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. López AS; Alegre E; LeMaoult J; Carosella E; González A Mol Immunol; 2006 Jul; 43(14):2151-60. PubMed ID: 16490253 [TBL] [Abstract][Full Text] [Related]
10. Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo. Wang Q; Ding Y; Song P; Zhu H; Okon I; Ding YN; Chen HZ; Liu DP; Zou MH Circulation; 2017 Dec; 136(23):2271-2283. PubMed ID: 28978552 [TBL] [Abstract][Full Text] [Related]
11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666 [TBL] [Abstract][Full Text] [Related]
13. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Hashimoto D; Asakura S; Matsuoka K; Sakoda Y; Koyama M; Aoyama K; Tanimoto M; Teshima T Eur J Immunol; 2007 Jan; 37(1):271-81. PubMed ID: 17154260 [TBL] [Abstract][Full Text] [Related]
14. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. Georgantas RW; Bohana-Kashtan O; Civin CI Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590 [TBL] [Abstract][Full Text] [Related]
15. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation. Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783 [TBL] [Abstract][Full Text] [Related]
17. High expression of IMPACT protein promotes resistance to indoleamine 2,3-dioxygenase-induced cell death. Habibi D; Jalili RB; Forouzandeh F; Ong CJ; Ghahary A J Cell Physiol; 2010 Oct; 225(1):196-205. PubMed ID: 20648630 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. Terness P; Bauer TM; Röse L; Dufter C; Watzlik A; Simon H; Opelz G J Exp Med; 2002 Aug; 196(4):447-57. PubMed ID: 12186837 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. Drobyski WR; Majewski D; Ozker K; Hanson G J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263 [TBL] [Abstract][Full Text] [Related]